Your browser doesn't support javascript.
loading
Artificial intelligence for cardiovascular disease risk assessment in personalised framework: a scoping review.
Singh, Manasvi; Kumar, Ashish; Khanna, Narendra N; Laird, John R; Nicolaides, Andrew; Faa, Gavino; Johri, Amer M; Mantella, Laura E; Fernandes, Jose Fernandes E; Teji, Jagjit S; Singh, Narpinder; Fouda, Mostafa M; Singh, Rajesh; Sharma, Aditya; Kitas, George; Rathore, Vijay; Singh, Inder M; Tadepalli, Kalyan; Al-Maini, Mustafa; Isenovic, Esma R; Chaturvedi, Seemant; Garg, Deepak; Paraskevas, Kosmas I; Mikhailidis, Dimitri P; Viswanathan, Vijay; Kalra, Manudeep K; Ruzsa, Zoltan; Saba, Luca; Laine, Andrew F; Bhatt, Deepak L; Suri, Jasjit S.
Afiliação
  • Singh M; Stroke Monitoring and Diagnostic Division, AtheroPoint™, Roseville, CA, 95661, USA.
  • Kumar A; Bennett University, 201310, Greater Noida, India.
  • Khanna NN; Bennett University, 201310, Greater Noida, India.
  • Laird JR; Department of Cardiology, Indraprastha APOLLO Hospitals, New Delhi, 110001, India.
  • Nicolaides A; Heart and Vascular Institute, Adventist Health St. Helena, St Helena, CA, 94574, USA.
  • Faa G; Vascular Screening and Diagnostic Centre and University of Nicosia Medical School, Cyprus.
  • Johri AM; Department of Pathology, University of Cagliari, Cagliari, Italy.
  • Mantella LE; Department of Medicine, Division of Cardiology, Queen's University, Kingston, Canada.
  • Fernandes JFE; Department of Medicine, Division of Cardiology, University of Toronto, Toronto, Canada.
  • Teji JS; Department of Vascular Surgery, University of Lisbon, Lisbon, Portugal.
  • Singh N; Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 60611, USA.
  • Fouda MM; Department of Food Science and Technology, Graphic Era Deemed to Be University, Dehradun, Uttarakhand, 248002, India.
  • Singh R; Department of Electrical and Computer Engineering, Idaho State University, Pocatello, ID, 83209, USA.
  • Sharma A; Department of Research and Innovation, Uttaranchal Institute of Technology, Uttaranchal University, Dehradun, 248007, India.
  • Kitas G; Division of Cardiovascular Medicine, University of Virginia, Charlottesville, 22901, VA, USA.
  • Rathore V; Academic Affairs, Dudley Group NHS Foundation Trust, DY1, Dudley, UK.
  • Singh IM; Nephrology Department, Kaiser Permanente, Sacramento, CA, 95823, USA.
  • Tadepalli K; Stroke Monitoring and Diagnostic Division, AtheroPoint™, Roseville, CA, 95661, USA.
  • Al-Maini M; Jio Artificial Intelligence, Centre of Excellence, India.
  • Isenovic ER; Allergy, Clinical Immunology and Rheumatology Institute, Toronto, ON, L4Z 4C4, Canada.
  • Chaturvedi S; Department of Radiobiology and Molecular Genetics, National Institute of The Republic of Serbia, University of Belgrade, 110010, Serbia.
  • Garg D; Department of Neurology & Stroke Program, University of Maryland, Baltimore, MD, USA.
  • Paraskevas KI; SR University, Warangal, Telangana, India.
  • Mikhailidis DP; Department of Vascular Surgery, Central Clinic of Athens, Athens, Greece.
  • Viswanathan V; Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London (UCL), London, UK.
  • Kalra MK; MV Diabetes Centre, Royapuram, Chennai, Tamil Nadu, 600013, India.
  • Ruzsa Z; Department of Radiology, Harvard Medical School, Boston, MA, USA.
  • Saba L; Invasive Cardiology Division, University of Szeged, Szeged, Hungary.
  • Laine AF; Department of Radiology, Azienda Ospedaliero Universitaria, 40138, Cagliari, Italy.
  • Bhatt DL; Departments of Biomedical and Radiology, Columbia University, New York, NY, USA.
  • Suri JS; Icahn School of Medicine, Mount Sinai, NY, USA.
EClinicalMedicine ; 73: 102660, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38846068
ABSTRACT

Background:

The field of precision medicine endeavors to transform the healthcare industry by advancing individualised strategies for diagnosis, treatment modalities, and predictive assessments. This is achieved by utilizing extensive multidimensional biological datasets encompassing diverse components, such as an individual's genetic makeup, functional attributes, and environmental influences. Artificial intelligence (AI) systems, namely machine learning (ML) and deep learning (DL), have exhibited remarkable efficacy in predicting the potential occurrence of specific cancers and cardiovascular diseases (CVD).

Methods:

We conducted a comprehensive scoping review guided by the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) framework. Our search strategy involved combining key terms related to CVD and AI using the Boolean operator AND. In August 2023, we conducted an extensive search across reputable scholarly databases including Google Scholar, PubMed, IEEE Xplore, ScienceDirect, Web of Science, and arXiv to gather relevant academic literature on personalised medicine for CVD. Subsequently, in January 2024, we extended our search to include internet search engines such as Google and various CVD websites. These searches were further updated in March 2024. Additionally, we reviewed the reference lists of the final selected research articles to identify any additional relevant literature.

Findings:

A total of 2307 records were identified during the process of conducting the study, consisting of 564 entries from external sites like arXiv and 1743 records found through database searching. After 430 duplicate articles were eliminated, 1877 items that remained were screened for relevancy. In this stage, 1241 articles remained for additional review after 158 irrelevant articles and 478 articles with insufficient data were removed. 355 articles were eliminated for being inaccessible, 726 for being written in a language other than English, and 281 for not having undergone peer review. Consequently, 121 studies were deemed suitable for inclusion in the qualitative synthesis. At the intersection of CVD, AI, and precision medicine, we found important scientific findings in our scoping review. Intricate pattern extraction from large, complicated genetic datasets is a skill that AI algorithms excel at, allowing for accurate disease diagnosis and CVD risk prediction. Furthermore, these investigations have uncovered unique genetic biomarkers linked to CVD, providing insight into the workings of the disease and possible treatment avenues. The construction of more precise predictive models and personalised treatment plans based on the genetic profiles of individual patients has been made possible by the revolutionary advancement of CVD risk assessment through the integration of AI and genomics.

Interpretation:

The systematic methodology employed ensured the thorough examination of available literature and the inclusion of relevant studies, contributing to the robustness and reliability of the study's findings. Our analysis stresses a crucial point in terms of the adaptability and versatility of AI solutions. AI algorithms designed in non-CVD domains such as in oncology, often include ideas and tactics that might be modified to address cardiovascular problems.

Funding:

No funding received.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: EClinicalMedicine Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: EClinicalMedicine Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos